AstraZeneca Q3 Adj EPS $0.86 Beats $0.84 Estimate, Sales $11.49B Miss $11.66B Estimate
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's Q3 adjusted earnings per share of $0.86 beat the analyst consensus estimate of $0.84 by 2.98 percent, a 2.98 percent increase from the same period last year. However, the company's quarterly sales of $11.49 billion missed the analyst consensus estimate of $11.66 billion by 1.44 percent, though it is a 4.64 percent increase from the same period last year.
November 09, 2023 | 7:56 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AstraZeneca's Q3 earnings beat estimates but sales missed, which could lead to mixed market reactions.
AstraZeneca's Q3 earnings beat estimates, which is positive for the stock. However, the company's sales missed estimates, which is negative. These two factors could offset each other, leading to a neutral impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100